Sökning: WFRF:(Islam Jakobsson Protik) >
Rituximab in multip...
Rituximab in multiple sclerosis : a retrospective observational study on safety and efficacy
-
- Salzer, Jonatan (författare)
- Umeå universitet,Klinisk neurovetenskap
-
- Svenningsson, Rasmus (författare)
- Umeå universitet,Klinisk neurovetenskap,Department of Clinical Neuroscience, Danderyd Hospital, Karolinska Institutet, Stockholm
-
- Alping, Peter (författare)
- Karolinska Institutet
-
visa fler...
-
Novakova, Lenka (författare)
-
Björck, Anna (författare)
-
- Fink, Katharina (författare)
- Karolinska Institutet
-
- Islam-Jakobsson, Protik (författare)
- Umeå universitet,Klinisk neurovetenskap
-
Malmeström, Clas (författare)
-
Axelsson, Markus (författare)
-
- Vågberg, Mattias (författare)
- Umeå universitet,Klinisk neurovetenskap
-
- Sundström, Peter (författare)
- Umeå universitet,Klinisk neurovetenskap
-
Lycke, Jan (författare)
-
- Piehl, Fredrik (författare)
- Karolinska Institutet
-
- Svenningsson, Anders (författare)
- Karolinska Institutet,Umeå universitet,Klinisk neurovetenskap,Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm
-
visa färre...
-
(creator_code:org_t)
- 2016
- 2016
- Engelska.
-
Ingår i: Neurology. - 0028-3878 .- 1526-632X. ; 87:20, s. 2074-2081
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://umu.diva-por... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objective: To investigate the safety and efficacy of rituximab in multiple sclerosis (MS). Methods: In this retrospective uncontrolled observational multicenter study, off-label rituximab-treated patients with MS were identified through the Swedish MS register. Outcome data were collected from the MS register and medical charts. Adverse events (AEs) grades 2-5 according to the Common Terminology Criteria for Adverse Events were recorded. Results: A total of 822 rituximab-treated patients with MS were identified: 557 relapsing-remitting MS (RRMS), 198 secondary progressive MS (SPMS), and 67 primary progressive MS (PPMS). At baseline, 26.2% had contrast-enhancing lesions (CELs). Patients were treated with 500 or 1,000 mg rituximab IV every 6-12 months, during a mean 21.8 (SD 14.3) months. During treatment, the annualized relapse rates were 0.044 (RRMS), 0.038 (SPMS), and 0.015 (PPMS), and 4.6% of patients displayed CELs. Median Expanded Disability Status Scale remained unchanged in RRMS (p = 0.42) and increased by 0.5 and 1.0 in SPMS and PPMS, respectively (p = 0.10 and 0.25). Infusion-related AEs occurred during 7.8% of infusions and most were mild. A total of 89 AEs grades >= 2 (of which 76 infections) were recorded in 72 patients. No case of progressive multifocal leukoencephalopathy was detected. Conclusions: This is the largest cohort of patients with MS treated with rituximab reported so far. The safety, clinical, and MRI findings in this heterogeneous real-world cohort treated with different doses of rituximab were similar to those reported in previous randomized controlled trials on B-cell depletion therapy in MS. Classification of evidence: This study provides Class IV evidence that for patients with MS, rituximab is safe and effective.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Salzer, Jonatan
-
Svenningsson, Ra ...
-
Alping, Peter
-
Novakova, Lenka
-
Björck, Anna
-
Fink, Katharina
-
visa fler...
-
Islam-Jakobsson, ...
-
Malmeström, Clas
-
Axelsson, Markus
-
Vågberg, Mattias
-
Sundström, Peter
-
Lycke, Jan
-
Piehl, Fredrik
-
Svenningsson, An ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Neurovetenskaper
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Neurologi
- Artiklar i publikationen
-
Neurology
- Av lärosätet
-
Umeå universitet
-
Karolinska Institutet